EUVIMEDEUVIMED entdecken
Open Access

Liquid Chromatography–Mass Spectrometry Screening of Cyclophosphamide DNA Damage In Vitro and in Patients Undergoing Chemotherapy Treatment

Valeria Guidolin iD, Foster C Jacobs, Margaret L MacMillan, Peter W Villalta iD, Silvia Balbo iD

Chemical Research in Toxicology · 2023

DOI: 10.1021/acs.chemrestox.3c00008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemical Research in Toxicology, 2023. Verfasst von Valeria Guidolin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota 55455, United States. Hauptthemen laut MEDLINE: DNA Adducts, Anemia. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

DNA alkylating drugs have been used as frontline medications to treat cancer for decades. Their chemical reaction with DNA leads to the blockage of DNA replication, which impacts cell replication. While this impacts rapidly dividing cancerous cells, this process is not selective and results in highly variable and often severe side effects in patients undergoing alkylating-drug based therapies. The development of biomarkers to identify patients who effectively respond with tolerable toxicities vs patients who develop serious side effects is needed. Cyclophosphamide (CPA) is a commonly used chemotherapeutic drug and lacks biomarkers to evaluate its therapeutic effect and toxicity. Upon administration, CPA is metabolically activated and converted to phosphoramide mustard and acrolein, which are responsible for its efficacy and toxicity, respectively. Previous studies have explored the detection of the major DNA adduct of CPA, the interstrand DNA-DNA cross-link G-NOR-G, finding differences in the cross-link amount between Fanconi Anemia and non-Fanconi Anemia patients undergoing chemotherapy treatment. In this study, we take advantage of our DNA adductomic approach to comprehensively profile CPA's and its metabolites' reactions with DNA in vitro and in patients undergoing CPA-based chemotherapy. This investigation led to the detection of 40 DNA adducts in vitro and 20 DNA adducts in patients treated with CPA. Moreover, acrolein-derived DNA adducts were quantified in patient samples. The results suggest that CPA-DNA damage is very complex, and an evaluation of DNA adduct profiles is necessary when evaluating the relationship between CPA-DNA damage and patient outcome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA AdductsAnemiaHumansAcroleinCyclophosphamideAlkylating AgentsDNA DamageDNAMass SpectrometryChromatography, Liquid

Substanzen

DNA AdductsAcroleinCyclophosphamideAlkylating AgentsDNA

Autor:innen und Institutionen

  • Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota 55455, United States.
  • School of Public Health, University of Minnesota, Minneapolis, Minnesota 55455, United States.
  • Blood and Marrow Transplantation & Cellular Therapy Program, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota 55455, United States.
  • Department of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota 55455, United States.

ORCID-Profile: Valeria Guidolin, Peter W Villalta, Silvia Balbo

Förderung

  • NCI NIH HHS

Zitieren

APA

Guidolin, V., Jacobs, F. C., MacMillan, M. L., Villalta, P. W., & Balbo, S. (2023). Liquid Chromatography–Mass Spectrometry Screening of Cyclophosphamide DNA Damage In Vitro and in Patients Undergoing Chemotherapy Treatment. Chemical Research in Toxicology. https://doi.org/10.1021/acs.chemrestox.3c00008

Vancouver

Guidolin V, Jacobs FC, MacMillan ML, Villalta PW, Balbo S. Liquid Chromatography–Mass Spectrometry Screening of Cyclophosphamide DNA Damage In Vitro and in Patients Undergoing Chemotherapy Treatment. Chemical Research in Toxicology. 2023. doi:10.1021/acs.chemrestox.3c00008

BibTeX
@article{Guidolin2023,
  author = {Guidolin, Valeria and Jacobs, Foster C and MacMillan, Margaret L and Villalta, Peter W and Balbo, Silvia},
  title = {Liquid Chromatography–Mass Spectrometry Screening of Cyclophosphamide DNA Damage In Vitro and in Patients Undergoing Chemotherapy Treatment},
  journal = {Chemical Research in Toxicology},
  year = {2023},
  doi = {10.1021/acs.chemrestox.3c00008}
}
Kostenlos starten →